Editas will earn an upfront payment of $25 million to launch three research programs to apply CRISPR/Cas9 and TALEN genome editing to Juno's immunotherapies.
The bodies will assemble an international committee to guide future research and have planned a summit this fall for experts to discuss the implications of the technology.
Commercial software packages with a suite of additional features offer an alternative to academic guide RNA design tools for CRISPR/Cas9 genome editing.
High-throughput, systematic screens found 25 protein domains essential to AML, including six that are already drug targets in clinical trials.
The North Carolina-based firm plans to use the money to continue development of its Arcus genome editing platform.
In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.
Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.
A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.
In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.